{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:24:10Z","timestamp":1793391850188,"version":"4.5.0"},"reference-count":44,"publisher":"Becaris Publishing Limited","issue":"8","funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["NO.81874402 and NO.82174128"],"award-info":[{"award-number":["NO.81874402 and NO.82174128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            20\u00a0mg of vonoprazan (VPZ20) is recommended in most countries to treat erosive esophagitis (EE). Whether other doses of vonoprazan, such as 5\u00a0mg (VPZ5), 10\u00a0mg (VPZ10), 20\u00a0mg (VPZ20), and 40\u00a0mg (VPZ40) are more effective is unknown.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Three databases were electronically searched to identify studies published before November 2021. Network meta-analysis was performed using STATA 14.0.\n            <jats:bold>Results:<\/jats:bold>\n            VPZ20 and VPZ40 were comparable to PPI, VPZ5\u00a0and VPZ10 in 4- and 8-week healing rates, and this was also detected in patients with refractory EE. All regimens resulted in similar treatment-emergent adverse events (TEAEs). However, VPZ40 ranked first for healing rate and TEAEs; however, VPZ20 ranked worst for TEAEs.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Different doses of VPZ are comparable in efficacy and safety, but VPZ40 may be best in both effectiveness and safety.\n          <\/jats:p>","DOI":"10.57264\/cer-2022-0165","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T10:21:44Z","timestamp":1689848504000},"source":"Crossref","is-referenced-by-count":4,"title":["Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis"],"prefix":"10.57264","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2108-9131","authenticated-orcid":false,"given":"Jie","family":"He","sequence":"first","affiliation":[{"name":"Gastrology\/Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8611-8861","authenticated-orcid":false,"given":"Yuanyuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Apartment of Mental disease\/Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200000, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Bai","sequence":"additional","affiliation":[{"name":"Oncology\/Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi, 030000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Gastrology\/Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6410-3004","authenticated-orcid":false,"given":"Yongshun","family":"Sun","sequence":"additional","affiliation":[{"name":"Gastrology\/Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"8","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus","volume":"101","author":"Vakil N","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 101(8), 1900\u20131920; quiz 43 (2006).","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis","volume":"67","author":"Eusebi LH","year":"2018","unstructured":"Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 67(3), 430\u2013440 (2018).","journal-title":"Gut"},{"issue":"2","key":"e_1_3_6_5_2","first-page":"1","article-title":"The natural history of gastro-esophageal reflux disease: a comprehensive review","volume":"30","author":"Savarino E","year":"2017","unstructured":"Savarino E, de Bortoli N, De Cassan C The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis. Esophagus 30(2), 1\u20139 (2017).","journal-title":"Dis. Esophagus"},{"issue":"39","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.3748\/wjg.v19.i39.6523","article-title":"Gastroesophageal reflux disease: update on inflammation and symptom perception","volume":"19","author":"Altomare A","year":"2013","unstructured":"Altomare A, Guarino MP, Cocca S, Emerenziani S, Cicala M. Gastroesophageal reflux disease: update on inflammation and symptom perception. World J. Gastroenterol. 19(39), 6523\u20136528 (2013).","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"e_1_3_6_7_2","first-page":"2","article-title":"Gastroesophageal reflux disease in Asia: a historical perspective and present challenges","volume":"26","author":"Goh KL","year":"2011","unstructured":"Goh KL. Gastroesophageal reflux disease in Asia: a historical perspective and present challenges. J. Gastroenterol. Hepatol. 26(Suppl. 1), 2\u201310 (2011).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida K","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment. Pharmacol. Ther. 43(2), 240\u2013251 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1590\/S0004-28032010000100017","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus","volume":"47","author":"Moraes-Filho JP","year":"2010","unstructured":"Moraes-Filho JP, Navarro-Rodriguez T, Barbuti R, Eisig J, Chinzon D, Bernardo W. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus. Arq. Gastroenterol. 47(1), 99\u2013115 (2010).","journal-title":"Arq. Gastroenterol."},{"issue":"6","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00464-014-3431-z","article-title":"EAES recommendations for the management of gastroesophageal reflux disease","volume":"28","author":"Fuchs KH","year":"2014","unstructured":"Fuchs KH, Babic B, Breithaupt W EAES recommendations for the management of gastroesophageal reflux disease. Surg. Endosc. 28(6), 1753\u20131773 (2014).","journal-title":"Surg. Endosc."},{"issue":"8","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015","volume":"51","author":"Iwakiri K","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J. Gastroenterol. 51(8), 751\u2013767 (2016).","journal-title":"J. Gastroenterol."},{"issue":"2","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cgh.2011.07.008","article-title":"Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease","volume":"10","author":"Hungin AP","year":"2012","unstructured":"Hungin AP, Hill C, Molloy-Bland M, Raghunath A. Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin. Gastroenterol. Hepatol. 10(2), 109\u2013116 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial","volume":"96","author":"Richter JE","year":"2001","unstructured":"Richter JE, Kahrilas PJ, Johanson J Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am. J. Gastroenterol. 96(3), 656\u2013665 (2001).","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3164\/jcbn.14-144","article-title":"Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in Japan","volume":"57","author":"Mizuno H","year":"2015","unstructured":"Mizuno H, Matsuhashi N, Sakaguchi M Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in Japan. J. Clin. Biochem. Nutr. 57(3), 233\u2013238 (2015).","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"3","key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.111.179556","article-title":"A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals","volume":"337","author":"Hori Y","year":"2011","unstructured":"Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J. Pharmacol. Exp. Ther. 337(3), 797\u2013804 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bcp.2011.02.009","article-title":"A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands","volume":"81","author":"Matsukawa J","year":"2011","unstructured":"Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem. Pharmacol. 81(9), 1145\u20131151 (2011).","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1087057111421004","article-title":"High-throughput screening of potassium-competitive acid blockers","volume":"17","author":"Kondo M","year":"2012","unstructured":"Kondo M, Kawamoto M, Hasuoka A, Kajino M, Inatomi N, Tarui N. High-throughput screening of potassium-competitive acid blockers. J. Biomol. Screen. 17(2), 177\u2013182 (2012).","journal-title":"J. Biomol. Screen."},{"issue":"2","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000456072","article-title":"Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis","volume":"95","author":"Hoshino S","year":"2017","unstructured":"Hoshino S, Kawami N, Takenouchi N Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 95(2), 156\u2013161 (2017).","journal-title":"Digestion"},{"issue":"1","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10620-020-06141-5","article-title":"Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis","volume":"66","author":"Cheng Y","year":"2021","unstructured":"Cheng Y, Liu J, Tan X Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig. Dis. Sci. 66(1), 19\u201328 (2021).","journal-title":"Dig. Dis. Sci."},{"issue":"6","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","article-title":"Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis","volume":"42","author":"Ashida K","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment. Pharmacol. Ther. 42(6), 685\u2013695 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1756283X17705329","article-title":"A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis","volume":"10","author":"Iwakiri K","year":"2017","unstructured":"Iwakiri K, Sakurai Y, Shiino M A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap. Adv. Gastroenterol. 10(6), 439\u2013451 (2017).","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"1","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias S","year":"2019","unstructured":"Dias S, Caldwell DM. Network meta-analysis explained. Arch. Dis. Child. Fetal Neonatal Ed. 104(1), F8\u2013F12 (2019).","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"issue":"11","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162(11), 777\u2013784 (2015).","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti G","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64(2), 163\u2013171 (2011).","journal-title":"J. Clin. Epidemiol."},{"key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).","journal-title":"BMJ"},{"issue":"2","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani A","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann. Intern. Med. 159(2), 130\u2013137 (2013).","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti G","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res. Synth. Methods 3(2), 80\u201397 (2012).","journal-title":"Res. Synth. Methods"},{"issue":"8","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jval.2015.10.002","article-title":"Using generalized linear mixed models to evaluate inconsistency within a network meta-analysis","volume":"18","author":"Tu YK","year":"2015","unstructured":"Tu YK. Using generalized linear mixed models to evaluate inconsistency within a network meta-analysis. Value Health 18(8), 1120\u20131125 (2015).","journal-title":"Value Health"},{"issue":"2","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins JP","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res. Synth. Methods 3(2), 98\u2013110 (2012).","journal-title":"Res. Synth. Methods"},{"issue":"8","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jval.2016.07.005","article-title":"Node-splitting generalized linear mixed models for evaluation of inconsistency in network meta-analysis","volume":"19","author":"Yu-Kang T","year":"2016","unstructured":"Yu-Kang T. Node-splitting generalized linear mixed models for evaluation of inconsistency in network meta-analysis. Value Health 19(8), 957\u2013963 (2016).","journal-title":"Value Health"},{"issue":"474","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu G","year":"2006","unstructured":"Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J. Am. Stat. Assoc. 101(474), 447\u2013459 (2006).","journal-title":"J. Am. Stat. Assoc."},{"issue":"20","key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu G","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105\u20133124 (2004).","journal-title":"Stat. Med."},{"issue":"1","key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw L","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst. Rev. 6(1), 79 (2017).","journal-title":"Syst. Rev."},{"issue":"7304","key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne JA","year":"2001","unstructured":"Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304), 101\u2013105 (2001).","journal-title":"BMJ"},{"key":"e_1_3_6_35_2","unstructured":"White I. Network: stata module to perform network meta-analysis. Statistical software components (2017). https:\/\/econpapers.repec.org\/software\/bocbocode\/S458319.htm"},{"issue":"10","key":"e_1_3_6_36_2","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani A","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 8(10), e76654 (2013).","journal-title":"PLoS One"},{"issue":"8","key":"e_1_3_6_37_2","first-page":"A513","article-title":"A phase 3, randomized, double-blind, multicentre study to evaluate the safety and efficacy of TAK-438 20 mg once daily compared to lansoprazole 30 mg once daily in patients with erosive esophagitis: results from a chinese subcohort","volume":"6","author":"Chen M","year":"2018","unstructured":"Chen M, Dai N, Fei G, Chong CF, Funao N, Zhang S. A phase 3, randomized, double-blind, multicentre study to evaluate the safety and efficacy of TAK-438 20 mg once daily compared to lansoprazole 30 mg once daily in patients with erosive esophagitis: results from a chinese subcohort. United European Gastroenterol. J. 6(8), A513 (2018).","journal-title":"United European Gastroenterol. J."},{"issue":"9","key":"e_1_3_6_38_2","first-page":"18","article-title":"Clinical efficacy and safety of vonoprazan in the treatment of refractory reflux esophagitis [in Chinese]","volume":"14","author":"Huang B","year":"2021","unstructured":"Huang B, Cui DJ, Zhao X Clinical efficacy and safety of vonoprazan in the treatment of refractory reflux esophagitis [in Chinese]. Chin. J. Clin. Rational Drug Use 14(9A), 18\u201320 (2021).","journal-title":"Chin. J. Clin. Rational Drug Use"},{"issue":"3","key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10388-020-00798-7","article-title":"Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study","volume":"18","author":"Okanobu H","year":"2021","unstructured":"Okanobu H, Kohno T, Mouri R Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study. Esophagus 18(3), 669\u2013675 (2021).","journal-title":"Esophagus"},{"issue":"3","key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10620-018-5365-0","article-title":"Short-term symptomatic relief in gastroesophageal reflux disease: a comparative study of esomeprazole and vonoprazan","volume":"64","author":"Sakurai K","year":"2019","unstructured":"Sakurai K, Suda H, Fujie S Short-term symptomatic relief in gastroesophageal reflux disease: a comparative study of esomeprazole and vonoprazan. Dig. Dis. Sci. 64(3), 815\u2013822 (2019).","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"e_1_3_6_41_2","doi-asserted-by":"crossref","first-page":"S-302","DOI":"10.1016\/S0016-5085(19)37576-6","article-title":"Sa1194 \u2013 1-year interim analysis results of vision trial: a randomized, open-label study to evaluate a long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis","volume":"156","author":"Uemura N","year":"2019","unstructured":"Uemura N, Kinoshita Y, Haruma K Sa1194 \u2013 1-year interim analysis results of vision trial: a randomized, open-label study to evaluate a long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Gastroenterology 156(1 Suppl. 6), S-302\u2013S-3 (2019).","journal-title":"Gastroenterology"},{"issue":"2","key":"e_1_3_6_42_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao Y","year":"2020","unstructured":"Xiao Y, Zhang S, Dai N Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut 69(2), 224\u2013230 (2020).","journal-title":"Gut"},{"issue":"39","key":"e_1_3_6_43_2","doi-asserted-by":"crossref","first-page":"e8120","DOI":"10.1097\/MD.0000000000008120","article-title":"Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: a PRISMA-compliant network meta-analysis","volume":"96","author":"Li MJ","year":"2017","unstructured":"Li MJ, Li Q, Sun M, Liu LQ. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: a PRISMA-compliant network meta-analysis. Medicine (Baltimore) 96(39), e8120 (2017).","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"e_1_3_6_44_2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s10620-009-1004-0","article-title":"Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey","volume":"55","author":"Friedenberg FK","year":"2010","unstructured":"Friedenberg FK, Hanlon A, Vanar V Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey. Dig. Dis. Sci. 55(7), 1911\u20131917 (2010).","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"e_1_3_6_45_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s10620-009-0927-9","article-title":"GERD-related health care utilization, therapy, and reasons for transfer of GERD patients between primary care providers and gastroenterologists in a US managed care setting","volume":"55","author":"Halpern R","year":"2010","unstructured":"Halpern R, Kothari S, Fuldeore M GERD-related health care utilization, therapy, and reasons for transfer of GERD patients between primary care providers and gastroenterologists in a US managed care setting. Dig. Dis. Sci. 55(2), 328\u2013337 (2010).","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"e_1_3_6_46_2","first-page":"S29","article-title":"Shortcomings of the first-generation proton pump inhibitors","volume":"13","author":"Tytgat GN","year":"2001","unstructured":"Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur. J. Gastroenterol. Hepatol. 13(Suppl. 1), S29\u2013S33 (2001).","journal-title":"Eur. J. Gastroenterol. Hepatol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2022-0165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T08:50:34Z","timestamp":1692175834000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2022-0165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.57264\/cer-2022-0165"],"URL":"https:\/\/doi.org\/10.57264\/cer-2022-0165","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"article-number":"e220165"}}